Role of Antileukotriene Drugs in Achievement of Bronchial Asthma Control

Ненашева, Н. М.

doi:10.21518/2079-701x-2017-18-44-55

Cited by 3 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effectiveness of the drug L-Montus kid® (montelukast) tablets (Levocetirizine 2.5 mg / montelukast 4 mg) production (Fourrts (India) Laboratories Pvt. Limited, India), was evaluated according to objective criteria -the dynamics of the clinical symptoms of asthma (the frequency of day and night attacks, the need for emergency care, the number of episodes of exacerbation of asthma, restriction of activity) in accordance with the recommended clinical control criteria [9,10]. Criteria for inclusion of the patient in the study: signed informed consent of the legal representative to participate in the trial; children of both sexes 2-5 years old with mild persistent bronchial asthma that does not meet the criteria for controlled, who did not receive basic asthma therapy for 3 months before the study.…”

Section: Methodsmentioning

confidence: 99%

Clinical Efficacy of Montelukast (L-Montus Kid®) in the Control of Mild Persistent Bronchial Asthma in Children

2020

jcr

View full text Add to dashboard Cite

The article summarizes clinical experience montelukast L-Montus kid® in achieving and maintaining control of mild persistent asthma in children 2-5 years of life. Found that treatment with montelukast (L-Montus kid®) in the form of tablets Levocetirizine 2.5mg, montelukast 4 mg in children aged 2-5 years with mild persistent asthma after 3 months of therapy effectively reduces the risk of daytime symptoms 80%, nighttime symptoms-70%; means to reduce the need for emergency assistance from 67% and also reduces the likelihood of acute asthma with 77%.

show abstract

Section: Methodsmentioning

confidence: 99%

Clinical Efficacy of Montelukast (L-Montus Kid®) in the Control of Mild Persistent Bronchial Asthma in Children

2020

jcr

View full text Add to dashboard Cite

show abstract

Prospective areas of pharmacotherapy for allergic rhinitis

Кryukov¹,

Nosulya²,

Kunelskaya³

et al. 2020

Ross. rinol.

View full text Add to dashboard Cite

Selection of therapy in smoking patients with bronchial asthma

Peredelskaya

Ненашева

Peredelskiy³

et al. 2021

Medicinskij sovet

View full text Add to dashboard Cite

Despite the evidence and logical fact that smoking and asthma are incompatible, many patients are smoke. The proportion of smokers among asthmatics is comparable to the proportion of smokers in the population. The proportion of smokers among asthmatics is comparable to the proportion of smokers in the population. Currently, the prevalence of tobacco use in the Russian Federation remains high at over 20%. In addition to active smoking, patients may be exposed to the negative effects of tobacco smoke through secondhand smoke. Smokers with asthma are more likely to have signs of poor disease control, and are more likely to seek exacerbation. However, a therapy strategy for them has not been worked out. For many randomized trials, patient smoking is the exclusion criterion, and therefore the effectiveness of a particular anti-asthma therapy in smokers is poorly understood. In addition, it is a known fact that smoking develops resistance to the main anti-asthma therapy, inhalation glucocorticosteroids. The article discusses the mechanism of exposure to tobacco smoke on lung tissue, the development of pathological processes under the influence of components of tobacco smoke and possible solutions to the problem. The mechanism of inflammatory and anti-inflammatory effects of various components of tobacco smoke. Particular attention is paid to the role of cysteinyl leukotrienes in the formation of inflammation in the lower respiratory tract in smoking patients with asthma and the possibility of treating these patients with leukotriene receptor antagonists. A review of studies conducted in patients with bronchial asthma and exposure to tobacco smoke in whom montelukast was used as therapy is presented. Provides information on the safety and side effects of the drug.

show abstract

Role of Antileukotriene Drugs in Achievement of Bronchial Asthma Control

Cited by 3 publications

References 50 publications

Clinical Efficacy of Montelukast (L-Montus Kid®) in the Control of Mild Persistent Bronchial Asthma in Children

Clinical Efficacy of Montelukast (L-Montus Kid®) in the Control of Mild Persistent Bronchial Asthma in Children

Prospective areas of pharmacotherapy for allergic rhinitis

Selection of therapy in smoking patients with bronchial asthma

Contact Info

Product

Resources

About